CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
378.18MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.7530xvs all stocks
52-Week Change
-29.50%vs all stocks
Market Capitalization
378.18MUSDvs all stocks (USD)
Enterprise Value
200.49MUSDvs all stocks (USD)
Forward P/E
-4.63xvs Biotechnology peers
Price to Book (MRQ)
2.07xvs Biotechnology peers
Enterprise to EBITDA
-2.67xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-27.91%vs Biotechnology peers
Return on Equity (TTM)
-45.95%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 17, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-75.02MUSDvs all stocks (USD)
Net Income (TTM)
-68.17MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-53.20MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-30.04MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-72.84MUSDvs all stocks (USD)
Pre-tax Income
-66.49MUSDFY2025 · Dec 31, 2025Net Income
-66.49MUSDFY2025 · Dec 31, 2025EBIT
-72.84MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-71.37MUSDFY2025 · Dec 31, 2025Research & Development
55.97MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
16.87MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.40MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-66.49MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-57.68MUSDFY2025 · Dec 31, 2025Free Cash Flow
-57.71MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
31.21MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-66.49MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.47MUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.37MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-664.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-369.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-25.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-194.56MUSDFY2025 · Dec 31, 2025Sale of Investments
101.28MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-93.31MUSDFY2025 · Dec 31, 2025Other Financing Charges
-9.66MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
128.33MUSDFY2025 · Dec 31, 2025Shares Outstanding
180.09MSharesUpdated Jul 17, 2026Float Shares
122.69MSharesUpdated Jul 17, 2026Shares Short
37.14MSharesUpdated Jul 17, 2026Short Ratio
9.75daysvs all stocks
Short % of Shares Outstanding
24.65%vs all stocks
% Held by Insiders
12.46%vs all stocks
% Held by Institutions
93.74%vs all stocks
Total Cash (MRQ)
194.69MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.08USDUpdated Jul 17, 2026Total Debt (MRQ)
9.79MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0525xvs Biotechnology peers
Current Ratio (MRQ)
19.04xvs Biotechnology peers
Book Value per Share (MRQ)
1.03USDUpdated Jul 17, 2026Total Assets
219.59MUSDvs all stocks (USD)
Total Current Assets
209.82MUSDFY2025 · Dec 31, 2025Total Liabilities
22.80MUSDFY2025 · Dec 31, 2025Total Non-current Assets
9.77MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
8.83MUSDFY2025 · Dec 31, 2025Total Current Liabilities
13.97MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
30.64MUSDFY2025 · Dec 31, 2025Other Short-term Investments
178.26MUSDFY2025 · Dec 31, 2025Accounts Payable
1.58MUSDFY2025 · Dec 31, 2025Short-term Debt
1.00MUSDFY2025 · Dec 31, 2025Long-term Debt
8.83MUSDFY2025 · Dec 31, 2025Common Stock (Book)
18.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-431.17MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
196.79MUSDvs all stocks (USD)
52-Week Low
1.61USDUpdated Jul 17, 202652-Week High
6.88USDUpdated Jul 17, 202652-Week Change
-29.50%vs all stocks
Beta
0.7530xvs all stocks
50-Day MA
2.07USDUpdated Jul 17, 2026200-Day MA
4.32USDUpdated Jul 17, 2026Avg 10-Day Volume
2.52MSharesUpdated Jul 17, 2026Avg 30-Day Volume
3.32MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
-0.3900USDUpdated Jul 17, 2026Other Income / Expense
-50.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.67
Altman Z-Score 7.18: safe zoneNotable
Altman Z-Score: 7.18
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Jilin Province Xidian Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rocket Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Akebia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Tianmu-Shan Pharmaceutical Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Upstream Bio, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Chengdu Huasun Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Larimar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lexeo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Changzheng Engineering Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineDecline With Range Expansion And Drawdown
Oculis Holding AG
2 interpretationsPartial Recovery After Sharp DeclineDecline With Range Expansion And Drawdown
Dongguan Tarry Electronics Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineDecline With Range Expansion And Drawdown